KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for REMERON(R) /Reflex(R) (mirtazapine)15 mg Tablets for the treatment of major depressive disorder.(1) The product was developed jointly with Meiji Seika Kabushiki Kaisha, Ltd. Schering-Plough and Meiji Seika will market the product under the trade names, REMERON(R) and Reflex(R), respectively. REMERON is currently available in more than 90 countries worldwide.
"REMERON came to us from the Organon research laboratories, and we are pleased that this new treatment option will now be available in Japan to help meet the needs of physicians and their patients suffering from depression," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "This approval is the eighth new product we have brought to the Japanese market since 2007 and represents important progress in extending our presence in Japan, a critical part of our geographic expansion."
REMERON (mirtazapine) is a noradrenergic and serotonergic antidepressant, with a mechanism of action that is different from that of selective serotonin reuptake inhibitors (SSRI) and serotonin-noradrenaline reuptake inhibitors (SNRI).
Important Safety Information About REMERON in the U.S.
In the United States, REMERONSolTab(R) is indicated for the treatment of major depressive disorder (MDD) in adults. REMERONSolTab(R) is not approved for use in pediatric patients, including children and teenagers.
Important Safety Information
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thi
|SOURCE Schering-Plough Corporation|
Copyright©2009 PR Newswire.
All rights reserved